Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.70 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.70 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.70 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.70 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.70 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.70 |
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.52 |
| ▸ | RXRA | P19793 | 4/20 | 0.49 |
| ▸ | RXRB | P28702 | 4/20 | 0.49 |
| ▸ | RXRG | P48443 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | PTGIR | P43119 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597847 | 0.84 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4597365 | 0.82 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4595856 | 0.81 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL28785934 | 0.81 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4597574 | 0.77 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11068250 | 0.77 | RXRA (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4598091 | 0.77 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4597785 | 0.76 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4597997 | 0.76 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27683622 | 0.75 | PSEN1 (0.67) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-12-04 | — | — | US | disclosed |
| EP-1773315-B1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1773315-A1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Limited (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008558-A1 | ARYLACETIC ACIDS AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER’S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300261-A1 | Arylacetic Acids and Related Compounds for Treatment of Alzheimer's Disease | PSEN2, PSEN1, NAT1 | PSEN1 2/4885PSEN2 1/4885APH1B 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.